The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

agentase.com

Founded Year

1998

Stage

Acquired - II | Acquired

Total Raised

$4.99M

About Agentase

Agentase develops biocatalyst preparations. The company works with a variety of federal agencies and corporate clients to develop enzyme-based systems tailored to specific performance criteria. Its technology addresses the perceived limitations of enzyme catalysis such as short catalytic lifetimes that restrict product shelf life and reduce catalyst productivity, acute environmental sensitivity that limits the range of acceptable conditions for catalysis, and vulnerability to thermal denaturation by developing application vehicles capable of protecting enzymes from adverse environments while enhancing their utility in a specific application.

Agentase Headquarter Location

2240 William Pitt Way

Pittsburgh, Pennsylvania, 15238,

United States

412-423-2100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Agentase Patents

Agentase has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/12/2013

9/27/2016

Ointments, Microbiology, Infectious diseases, Bacteria, Epidemiology

Grant

Application Date

6/12/2013

Grant Date

9/27/2016

Title

Related Topics

Ointments, Microbiology, Infectious diseases, Bacteria, Epidemiology

Status

Grant

Latest Agentase News

US Army to receive new CIDAS neurotoxin detection equipment

Sep 30, 2020

by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login

  • When was Agentase founded?

    Agentase was founded in 1998.

  • Where is Agentase's headquarters?

    Agentase's headquarters is located at 2240 William Pitt Way, Pittsburgh.

  • What is Agentase's latest funding round?

    Agentase's latest funding round is Acquired - II.

  • How much did Agentase raise?

    Agentase raised a total of $4.99M.

  • Who are the investors of Agentase?

    Investors of Agentase include FLIR Systems, ICx Technologies, U.S. Department of Defense, National Science Foundation, U.S. Army and 6 more.

  • Who are Agentase's competitors?

    Competitors of Agentase include Brainsgate, Erydel, Corium International, Savara, Vapore and 12 more.

You May Also Like

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

N
Nanomi

Nanomi develops membrane emulsification process technology and equipment for:nn * monodisperse emulsionsn * monodisperse double emulsionsn * monodisperse microspheres (e.g. drug delivery systems)n * monodisperse microbubblesnnHeart of the company's technology is a emulsification membrane, fabricated with microscopic precision by proven photolithographic processes from the semiconductor industry. Nanomi follow a partnering strategy where the combination of the company's technology and their application formulation will enable users to provide their customers with new high value-added products.n

M
MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.

N
Nano Discovery

Nano Discovery aims to provide customer-designed synthesis and development of a range of nanomaterials including nanoparticles, quantum dots, polymers, conjugated conducting polymers, nanofibers, nanotubes, nanoporous particles, colloidal particles (liposomes and vesicles), monolayer and multilayer thin films, and nanocomposite materials. Applications of the materials include biomolecular imaging, bioassay, drug delivery, cancer therapy, electronic materials, coatings and packaging for electronic devices, coatings for corrosion protection, conformable batteries, supercapcitors, and photovoltaic cells. The company also have developed or licensed some signature nanomaterial products which can be made-to-order for the company's customers.

W
Westfield Life Sciences Fund

Launched in July of 2000, the Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. Westfield's industry network developed by Mr. Muggia and his analytical team is critical to new idea generation.

N
NanoPass Technologies

NanoPass Technologies develops and commercializes painless intradermal (skin) delivery solutions for vaccines and large molecules. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.